Posted by Michael Wonder on 15 Sep 2022
Jasper Therapeutics announces FDA fast track designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency undergoing allogeneic haematopoietic stem cell transplantation
15 September 2022 - JSP191 is currently being evaluated in four on-going clinical studies in allogeneic haematopoietic stem cell transplant in patients with acute myeloid leukaemia/myelodysplastic syndromes, severe combined immunodeficiency, Fanconi anaemia and sickle cell disease.
Jasper Therapeutics today announced that JSP191, an anti-CD117 monoclonal antibody, has received fast track designation from the US FDA for the treatment of patients with severe combined immunodeficiency undergoing allogeneic haematopoietic stem cell transplantation.
